SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-230786
Filing Date
2023-09-08
Accepted
2023-09-07 17:37:53
Documents
12
Period of Report
2023-09-01
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d514862d8k.htm   iXBRL 8-K 21295
  Complete submission text file 0001193125-23-230786.txt   146189

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA antx-20230901.xsd EX-101.SCH 2873
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE antx-20230901_lab.xml EX-101.LAB 18736
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE antx-20230901_pre.xml EX-101.PRE 11722
6 EXTRACTED XBRL INSTANCE DOCUMENT d514862d8k_htm.xml XML 3460
Mailing Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027
Business Address 1800 EL CAMINO REAL, SUITE D MENLO PARK CA 94027 (650) 331-9090
AN2 Therapeutics, Inc. (Filer) CIK: 0001880438 (see all company filings)

IRS No.: 820606654 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-41331 | Film No.: 231243185
SIC: 2834 Pharmaceutical Preparations